{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:12:43Z","timestamp":1780593163526,"version":"3.54.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>During the synthesis of active pharmaceutical ingredients (APIs) there is a need for the development and validation of a simple and rapid high performance liquid chromatography (HPLC) method for the determination and quantification of the synthesized product and related by-products. An HPLC method gives a better understanding of how a synthesis is proceeding. A rapid and easy to use HPLC-UV (ultraviolet) method for the determination of difluprednate and monitoring of impurities generated during synthesis was developed and validated. A Shimadzu VP Series HPLC equipped with a LabSolutions software and UV detector set at 240\u00a0nm was used for analysis. The mobile phase consisted of phosphate buffer (pH\u00a06) and acetonitrile 50:50 (v\/v) and was eluted at a flow rate of 1.2\u00a0mL\/min. Separation took place on a reversed-phase Kinetex C18 column (150\u00a0\u00d7\u00a04.60\u00a0mm; 5\u00a0\u03bcm i.d.). Column temperature was set at 40\u00b0C. The developed method was found to have good linearity and acceptable accuracy and precision. The developed method may be effectively applied to determine products and by-products formed during synthetic reactions of steroids and to calculate the yield of the products obtained during each step of the synthesis.<\/jats:p>","DOI":"10.1093\/chromsci\/bmac108","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T09:29:30Z","timestamp":1673342970000},"page":"322-328","source":"Crossref","is-referenced-by-count":7,"title":["HPLC-UV Method Development and Validation to Monitor Difluprednate Synthesis"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9499-5875","authenticated-orcid":false,"given":"Nicolette","family":"Sammut Bartolo","sequence":"first","affiliation":[{"name":"University of Malta Department of Pharmacy, , Msida MSD 2080 , Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Vella Szijj","sequence":"additional","affiliation":[{"name":"University of Malta Department of Pharmacy, , Msida MSD 2080 , Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1900-7750","authenticated-orcid":false,"given":"Victor","family":"Ferrito","sequence":"additional","affiliation":[{"name":"University of Malta Department of Pharmacy, , Msida MSD 2080 , Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1196-0376","authenticated-orcid":false,"given":"Anthony","family":"Serracino-Inglott","sequence":"additional","affiliation":[{"name":"University of Malta Department of Pharmacy, , Msida MSD 2080 , Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"2023042616352284800_ref1","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.1016\/j.jfo.2019.02.002","article-title":"Eye and Behcet\u2019s disease","volume":"42","author":"Ksiaa","year":"2019","journal-title":"Journal Francais d'Ophtalmologie"},{"key":"2023042616352284800_ref2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.21037\/aes-2019-dmu-10","article-title":"Update on biologic therapies for juvenile idiopathic arthritis associated uveitis","volume":"6","author":"Thomas","year":"2021","journal-title":"Annals of Eye Science"},{"key":"2023042616352284800_ref3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/jop.2010.0059","article-title":"Durezol (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte 1% ophthalmic suspension in the treatment of endogenous anterior uveitis","volume":"26","author":"Foster","year":"2010","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"2023042616352284800_ref4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ajo.2021.09.008","article-title":"Effectiveness of difluprednate for the treatment of anterior scleritis","volume":"235","author":"Liberman","year":"2022","journal-title":"American Journal of Opthalmology"},{"key":"2023042616352284800_ref5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.2147\/OPTH.S6541","article-title":"Difluprednate for the prevention of ocular inflammation postsurgery: an update","volume":"5","author":"Donnenfeld","year":"2011","journal-title":"Clinical Ophthalmology"},{"key":"2023042616352284800_ref6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.4103\/0301-4738.114099","article-title":"Medical Management of Uveitis- Current Trends","volume":"61","author":"Babu","year":"2013","journal-title":"Indian Journal of Ophthalmology"},{"key":"2023042616352284800_ref7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1471-2415-13-39","article-title":"Local therapies for inflammatory eye disease in translation: past, present and future","volume":"13","author":"Tempest-Roe","year":"2013","journal-title":"BMC Ophthalmology"},{"key":"2023042616352284800_ref8","volume-title":"A second method of difluprednate prepared","author":"Hongbin","year":"2014"},{"key":"2023042616352284800_ref9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jpba.2014.09.028","article-title":"Difluprednate: more than meets the eye","volume":"102","author":"Giacobbe","year":"2015","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2023042616352284800_ref10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7869\/djo.2012.63","article-title":"Difluprednate: an overview","volume":"23","author":"Mithal","year":"2012","journal-title":"Delhi Journal of Ophthalmology"},{"key":"2023042616352284800_ref11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.2146\/news080060","article-title":"New topical corticosteroid treats postoperative ocular pain","volume":"65","author":"Thompson","year":"2008","journal-title":"American Journal of Health-System Pharmacy"},{"key":"2023042616352284800_ref15","first-page":"105","article-title":"Durezol treats postoperative inflammation and pain","volume":"Nov","author":"Korenfeld","year":"2008","journal-title":"Cataract Refract Surg Today"},{"key":"2023042616352284800_ref17","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.2147\/OPTH.S254705","article-title":"Difluprednate 0.05% versus prednisolone acetate post-phacoemulsification for inflammation and pain: an efficacy and safety clinical trial","volume":"Volume 14","author":"Palacio-Pastrana","year":"2020","journal-title":"Clinical Ophthalmology"},{"key":"2023042616352284800_ref16","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/eye.2016.132","article-title":"Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study","volume":"30","author":"Wilson","year":"2016","journal-title":"Eye"},{"key":"2023042616352284800_ref18","first-page":"e14673","article-title":"Therapeutic efficacy of difluprednate 0.05% versus prednisolone acetate 1% in controlling inflammation and macular oedema following phacoemulsification: an optical coherence tomography-based study","volume":"13","author":"Panda","year":"2021","journal-title":"Cureus"},{"key":"2023042616352284800_ref19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12348-017-0127-2","article-title":"Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate","volume":"7","author":"Mercado-Sesma","year":"2017","journal-title":"Journal of Ophthalmic Inflammation and Infection"},{"key":"2023042616352284800_ref20","volume-title":"17-butyrate, 21-ester derivatives of 6\u03b1, 9\u03b1-difluoroprednisolone, compositions and use","author":"Ercoli","year":"1973"},{"key":"2023042616352284800_ref21","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.chroma.2011.02.027","article-title":"Development of an orthogonal method for mometasone furoate impurity analysis using supercritical fluid chromatography","volume":"1218","author":"Wang","year":"2011","journal-title":"Journal of Chromatography. A"},{"key":"2023042616352284800_ref22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.chroma.2007.05.008","article-title":"Development and validation of a stability-indicating reversed-phase high performance liquid chromatography method for assay of betamethylepoxide and estimation of its related compounds","volume":"1157","author":"Xiao","year":"2007","journal-title":"Journal of Chromatography. A"},{"key":"2023042616352284800_ref23","first-page":"696","article-title":"A simple HPLC-UV method for the determination of clindamycin in human plasma","volume":"6","author":"Mifsud","year":"2014","journal-title":"Journal of Chemical and Pharmaceutical Research"},{"key":"2023042616352284800_ref24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.22159\/ijpps.2018v10i4.24817","article-title":"Implications of mobile phase composition and pH on the chromatographic separation of amitriptyline and its metabolite nortriptyline","volume":"10","author":"Mifsud Buhagiar","year":"2018","journal-title":"International Journal of Pharmacy Sciences"},{"key":"2023042616352284800_ref25","first-page":"96","article-title":"The combined effects of pH and acetonitrile composition on the separation of two lincosamide antibiotics","volume":"7","author":"Vella","year":"2014","journal-title":"Asian Journal of Pharmaceutical and Clinical Research"},{"key":"2023042616352284800_ref26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jchromb.2015.01.006","article-title":"A simple HPLC-UV method for the determination of ciprofloxacin in human plasma","volume":"989","author":"Vella","year":"2015","journal-title":"Journal of Chromatography B"},{"key":"2023042616352284800_ref27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1208\/s12249-020-01806-w","article-title":"An overview of drug substance manufacturing processes","volume":"21","author":"Wichrowski","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"2023042616352284800_ref28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1208\/s12249-020-01702-3","article-title":"Development and validation of sample preparation and an HPLC analytical method for dissolution testing in fed-state simulated gastric fluid - illustrating its application for ibuprofen and ketokonazole immediate release tablets","volume":"21","author":"Shah","year":"2020","journal-title":"AAPS PharmSciTech"},{"key":"2023042616352284800_ref29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1208\/s12249-013-9983-8","article-title":"Development and validation of a HPLC method for dissolution and stability assay of liquid-filled cyclosporine capsule drug products","volume":"14","author":"Xu","year":"2013","journal-title":"AAPS PharmSciTech"},{"key":"2023042616352284800_ref30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1208\/s12249-014-0228-2","article-title":"Simultaneous determination of acetaminophen and synthetic color(s) by derivative spectroscopy in syrup formulations and validation by HPLC: exposure risk of colors to children","volume":"16","author":"Rastogi","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"2023042616352284800_ref31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1208\/s12249-011-9735-6","article-title":"Sensitive and rapid HPLC quantification of tenofovir from hyaluronic acid-based nanomedicine","volume":"13","author":"Agrahari","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"2023042616352284800_ref32","first-page":"50","article-title":"Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide","volume":"1","author":"Demond","year":"2000","journal-title":"AAPS PharmSciTech"},{"key":"2023042616352284800_ref13","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2147\/OPTH.S12441","article-title":"Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%","volume":"4","author":"Stringer","year":"2010","journal-title":"Clinical Ophthalmology"},{"key":"2023042616352284800_ref33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jop.2010.0093","article-title":"Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits","volume":"27","author":"Tajika","year":"2011","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"key":"2023042616352284800_ref34","volume-title":"Compositions containing difluprednate","author":"Kimura","year":"2000"},{"key":"2023042616352284800_ref35","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/S0731-7085(02)00515-0","article-title":"Analysis of anti-inflammatory steroidal drug, difluprednate, in aqueous humour by combination of semi-micro HPLC and column switching method","volume":"30","author":"Yasueda","year":"2003","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2023042616352284800_ref36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijpharm.2005.05.036","article-title":"Formulation of an ophthalmic lipid emulsion containing an anti-inflammatory steroidal drug, Difluprednate","volume":"301","author":"Yamaguchi","year":"2005","journal-title":"International Journal of Pharmaceutics"},{"key":"2023042616352284800_ref37","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/00498254.2010.490308","article-title":"Metabolic profiles of difluprednate in rabbit ocular tissues after instillation of difluprednae ophthalmic emulsion","volume":"40","author":"Tajika","year":"2010","journal-title":"Xenobiotica"},{"key":"2023042616352284800_ref38","volume-title":"Oil-in water emulsion composition containing difluprednate and tobramycin","author":"Shikamura","year":"2012"},{"key":"2023042616352284800_ref39","volume-title":"High performance liquid chromatography (HPLC) determination method for related substances in difluprednate","author":"Pingguang","year":"2013"},{"key":"2023042616352284800_ref40","doi-asserted-by":"crossref","first-page":"113483","DOI":"10.1016\/j.jpba.2020.113483","article-title":"A multi-technique analytical approach for impurity profiling during synthesis: the case of difluprednate","volume":"190","author":"Sammut Bartolo","year":"2020","journal-title":"Journal of Pharmaceutical and Biomedical Analysis"},{"key":"2023042616352284800_ref14","first-page":"1","article-title":"Development and validation of analytical methods for simultaneous estimation of difluprednate and gatifloxacin in ophthalmic emulsion by UV-visible spectroscopy","volume":"3","author":"Patel","year":"2014","journal-title":"International Journal of Pharmaceutical Science Invention"},{"key":"2023042616352284800_ref41","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1208\/s12249-018-0973-8","article-title":"Application of ultra-centrifugation and bench-top 19F NMR for measuring drug phase partitioning for the ophthalmic oil-in-water emulsion products","volume":"19","author":"Wang","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"2023042616352284800_ref42","volume-title":"Proceedings of the International Conference on Harmonisation","author":"ICH Q2(R1)","year":"2005"},{"key":"2023042616352284800_ref43","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1128\/AAC.01126-10","article-title":"Development and validation of a high-performance liquid chromatography method for determination of cefquimone concentrations in sheep plasma and its application to pharmacokinetic studies","volume":"55","author":"Uney","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"12","key":"2023042616352284800_ref44","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1021\/cr068203e","article-title":"Synthesis and pharmacology of anti-inflammatory steroidal antedrugs","volume":"108","author":"Khan","year":"2008","journal-title":"Chemical Reviews"},{"key":"2023042616352284800_ref45","doi-asserted-by":"crossref","first-page":"5693","DOI":"10.1021\/ja01602a062","article-title":"16-hydroxylated steroids. IV. The synthesis of the 16\u03b1-hydroxy derivatives of 9\u03b1-halo-steroids","volume":"78","author":"Bernstein","year":"1956","journal-title":"Journal of the American Chemical Society"},{"key":"2023042616352284800_ref12","first-page":"89","article-title":"Pharmacokinetics of 22 new molecular entity drugs approved in 2008","volume":"9","author":"Gao","year":"2009","journal-title":"Asian Journal of Pharmacodynamics and Pharmacokinetics"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/61\/4\/322\/50071863\/bmac108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/61\/4\/322\/50071863\/bmac108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T16:37:20Z","timestamp":1682527040000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/61\/4\/322\/6979683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,1,9]]},"published-print":{"date-parts":[[2023,4,24]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmac108","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,4]]},"published":{"date-parts":[[2023,1,9]]}}}